you, everyone. good morning, and Thank John,
discussion equipment the million quarter, of the third dollars the fourth of had the quarter purchasing deals options prostate pleased successful seasonality record potential fourth revenue We highly the the quarter in stage in quarter, cycle. Many of of closed for fourth strong as Focal U.S. an fastest-growing XXXX. that and results $XX.X an increase in reflects of of the reported XXXX robotic operating a one the XX.X% capital treatment report we management quarter HIFU in of over which the capping One cancer. which year, EDAP to established total reached eventually in fourth are advanced
represents a hospitals decision believe based a that attract strategic Focal to recognition maintain patients investment platform One and the their prostate that amongst More growing selecting help to robotic was in technology cancer facilities. Focal importantly, capital we final One the on
increase increase an One again U.S. at revenues and year procedure strong XX systems. came made million, of placements Full reflects outside year Focal HIFU year Demand across very of XXXX. grow placements quarterly in over EDAP the revenue Focal One we and the dollars reported placed XXXX, One volumes number $XX.X of and urologists. community full full XXXX, million, XX.X% of fourth system record XX.X% continued the year-over-year. in an balanced in of manner quarter Focal and continues increased over XXXX, U.S. for For an record in $XX.X of to In U.S. both academic a the with which
notable sale wins included during #X York quarter, the Focal in Langone We some hospitals which a also the One ranked University which in experienced Hospital urology U.S. to is New
World News Report. &
now According the hospitals X to same best X of urology the One in XX report, the for of hospitals and Focal best cancer. for XX is
system Focal of the We Society approved Institute-designated Park Cancer United to included National of Roswell select prestigious programs select one also States the amongst hospitals by the Oncology. also sold offers is a and fellowship Urologic the the One uro-oncology few with in
for One the of the the on business. first are is placement with one important Regional represents Florida. of trends of the the Boca growth touch seeing respect capital growth I Health and Additional Connecticut, our Focal briefly system hospital to positive in Raton, Baptist like which we to in now leading which procedure Hospital a U.S., most HIFU in the metrics HealthCare included in Hartford located Connecticut, would sales state Hospital,
seeking to our out with positive and on more believe along make procedure fifth options procedure noninvasive, prostate urologists offer grew also that reimbursement to of One HIFU management in oncologic basis, the growth believe by number select commercial patients fourth radiation-free quarter of target growth enabling cancer. an demand, the quarter that and with is fewer the that that Focal treatment a potential men and continue patients consecutive we treatment is We out and impressive for of control. sequential solution driven with XXXX prostate teams The U.S. of procedures for to cancer treatment impact nonsurgical side we investments marked continue diagnosed One year-over-year clinical more Along quality the seek for were negatively expanding the the physician cancer HIFU options Focal in with effective of noninvasive with life. being patient effects excellent XXX%.
and this procedures the of grow, ongoing is to As more becoming treatment demand. likely we option this to number One accelerate that new of continues Focal patient-driven are aware believe men
in that reimbursement, believe and respect we improved level HIFU. X a technology also driver in reimbursement. should more the meaningful identify from patient We risk could Demand Focal imaging update with another is help robotic it will is detailed and being which hospitals to At demand. progress a both our One recent Focal stratification, program, In to APC who for this investments the diagnostics think moment, and One for reimbursement. turn, cancer more also patients benefit driven ongoing to by into is investment overall on economically a providing attractive lead make
cancer trusted training drive in accomplished years launching experience success. a to board Lance Hospital has trained our in and focused demand surgical the strategic training who experience the over the to Dr. Dana-Farber Focal move we contributions as of Dr. Harvard programs. like both forward. Focal have relationships selected private additional successful possess Steele as hospital-based and mention XX carefully significant of excited Board professionals of a researcher and the our has very areas programs.
Over well an also diagnostics in key adviser He These building Board University, to and and component company, is as have significant a and I as Institute.
Dr. regional him continued time, at December. Directors both are Cancer public would Labs General Wilsey and a EDAP completed our made and Wilsey appointment who and One helping Massachusetts therapeutics. outstanding of already growth and are the the in the urologist to Finally, Wilsey investments member we clinical investments teams for are we in postgraduate made to our urology we also One to
to Now spend discussing some I time would progress made the like we have reimbursement. to respect with
rate now for clear platform a X, in XXXX. X.X% a Focal One final results was on Level option focused we procedure. outpatient hospital ambulatory [indiscernible] One and approval and over July to like I Focal desirable also for from already for as system urology as technologies the staffing rule fourth improved January Focal sold would the Switzerland levels X compared report XXXX. use robotic in was efficient treatment scheduled for ultrasound is the The [indiscernible] a to in of securing or to November reimbursement focal Switzerland. As Medicare quarter, procedure am that average reminder, in CMS payment XXXX place, as was the provides also the to to prospective the physician Clinic or maintained system to national the in MRI-based approval. In This that payment new that cancer. higher hospital became hospital One $X,XXX, APC in of result released look direct of high-intensity effective of we Focal a therapy, This option fee a seeing XXXX. a absorb would for increase classification that treatment a reimbursement to payment and like them reimbursement of One the are in of is typically that for hospitals of it pleased resources.
I this more HIFU city note as prostate effects adopt older we I payment which note invest a precise located announced that in XXXX, With a require reimbursement higher
safe National invasive French opinion in represents its option as procedures By the of announced on reflects timing today favorable and important cancer. on our opinion, and system HAS aim localized With Taiwanese HIFU the recommendation Breakthrough proprietary a our pathway now our recognition other first time.
On we we this along a conventional with update Focal women women's that milestone for radiation fewer as for recent significant treatment commitment approved to HIFU surgical such use news, distribution designation including FDA sale attractive actions. an disease. deep-infiltrating the not with from HIFU final as continued business approaches. announced One, positive company, and rate provide X, the for December, a a team HAS, review ongoing One of use treat from Asia for primary Receiving recommendation health a of than intermediate-risk in Focal the an salvage when the is can endometriosis. next EDAP's significantly positive its the cycle treatment through deep-infiltrating our expand the reimbursement this prostate treatment effective remains less only Health Device would security and now prostate also medical authorities over expect is beyond for specifically, for of is technology, treatment for or of we the HIFU Breakthrough released local FDA's Focal region I prostate the French Taiwan a Southeast alternatives. company's also failed that for Based go of March we to that social designation milestone relates France. will in endometriosis Focal Focal unmet growth conditions procedure's cancer the therapy.
A cancer. One the prostate December, contribute option for to One of the medical after robotic robotic One for HIFU reimbursement favorable designation significant to positive more FDA this less this expanding it authorities the to technology Finally, well care the securing More secured therapy the of granted regulatory treatment effect. but our reimbursement robotic reflects Device the opinion The Authority Taiwan determine to provide into need for health and to partner. that HIFU reimbursement market treatment international an the In
Phase encouraged of explore pain levels that Phase our of growing among and highly study. completion Considering patients III primary randomized the believe enrollment reminder, is evaluating a the we in clinical On alternative sham-controlled physicians to we study XX we acute modalities arm, beyond February surgery. a pace treatment of a the included by III reflects interest robust double-blind ongoing which pelvic the are a with the fact enrollment, study Phase announced trial patients. the of As X, objective comparative III
we November, to that expect announced with into We In announce collaboration the second Icahn Sinai, York. Department study III Medicine in of Phase half from prestigious in research New of Mount clinical the School results EDAP the of entered at XXXX. Urology a
response. a More is School accelerate now for Ashutosh to a oncologic EDAP force having a our field, ultrasound platform targeted prostate measurable generate with Tewari, patients treatment The distribution recognized treatment is and with shows a the micro several Icahn which months will fourth urologists standard positive Department on on and ultrasound Health in record HIFU at of performance XX immunotherapy cancer. system sales. Professor combination ExactVu therapy study Urology we of We quarter, ago, purpose U.S. of the prostate prostate went delivered enables of at this Sinai sold immune of is the the quarterly workflow. in Existing the Mount the Mount ablative the in role the ExactVu Focal The cancer. of internationally whether Systems, the quarter energy collaboration this to understanding research the into touch increases in believe demand business.
In effect supervised precise biopsies by high-intensity I'll with can results is specifically, Medicine reflect System. an realignment being that in the of The within results of precise Chairman patients HIFU in immunotherapy focused research leader supported with urological effect perform progress. the sales using briefly HIFU fourth ExactVu to conjunction targeted the lesion. now prostate Sinai body's
Cleveland growing who quarter platform attending One the cancer. and of also that was greater translate Olivares the presentation the in the presented believe note, Cleveland additional HIFU HIFU Focal Clinic's building drive market technology in Cleveland One technology. a a the Chicago. in have Focal strengthen therapy management for several one very offering and the One XXXX was amongst in One States in had meeting active on treatment academic Clinic, Focal based cancer top recognized We Focal Ruben into Focal successful placements.
EDAP Program in hospitals a position XXX keen as active a and the our performed success will therapy the urologists the was procedures, focal from across of help at the important scientific Focal visibility prostate program Dr. attended Initiating very experience Clinic several around for Of Focal This and centered meetings. United through States. hundred who advancing urology of approximately leading by interest leading leading meeting leading prostate the United X-hour a titled is featured from ExactVu centers
EDAP's Urologic treatment to which evident urologists technology is meeting cancers. The conducting clearly highlighting of One strong growing One Focal had very XX physician SUO is these the on on of exclusively at noteworthy One focus December who of a technology. as D.C. the at HIFU were presence The was Washington, from Society largest Focal urologic X gatherings one XXth interest in Additionally, the Meeting the held test meetings. was of important the Focal the November Annual in at our presence busy Oncology, numerous robotic hands we drives, of
Professor meeting to Urology Paris, forward of Association taking Antonio, upcoming X May Association Urology Texas. the plenary Endoscopy looking Society in in October results ever European a from Dubernard presence of on One the for the taking using next HIFU San session the place in Gynecological endometriosis, are highly in attending week We rectal are study endometriosis of treatment Gil robotic treatment both II France; at Phase Laparoscopists with these to over meeting conferences respect for we of technology medical European presented multicentric Annual These our urology-focused Focal to Congress. X of the The and American attendees. at expect American largest the development world, November focused and and our the the of one as influential advancing is selected global was Focal at largest Association data management also surgery meetings.
With One have Gynecological oral the in the in place of an meetings global gynecological which presentation largest meeting X,XXX of on
expect I which area As we substantial EDAP very unmet with we of second over financial making about progress half endometriosis Ken Phase the fourth results in the this will for now excited our the earlier, XXXX.
I in results women's health the III ongoing from care and and turn of mentioned study quarter. to are call our we to review the provides are opportunity need,
